Rapamycin Just Matched Calorie Restriction Across 167 Lifespan Studies

Rapamycin Just Matched Calorie Restriction Across 167 Lifespan Studies

A meta-analysis of 167 lifespan studies across eight vertebrate species — fish, mice, rats, primates and four others — landed with quiet authority: rapamycin extends life almost as consistently as eating less. Researchers from the University of East Anglia and the University of Glasgow ran the numbers and found the two interventions essentially tied. Two roads, same finish line.

That result is a big deal because dietary restriction has been the field's gold standard for decades. Rapamycin — first scraped from Easter Island soil bacteria in the 1970s — wasn't supposed to match it. The meta-analysis says it does, and it does so reliably enough that the comparison is no longer a hypothesis. Whether long-term human use produces the same effect is still genuinely open: the meta-analysis aggregates animal data, and human trials of rapalogs (rapamycin-related drugs) are limited to short courses with surrogate endpoints rather than lifespan itself.

The uncomfortable implication is that an off-patent generic appears to do what calorie restriction does — but doctors still don't have the human endpoints they'd need to prescribe it for healthspan outside research settings.

Gobble's Take: The most consistent anti-aging compound in the animal data was discovered on a remote island in 1972 — and the field just collected its largest receipt yet that it actually works.

Source: Medical Xpress

A Sports Scientist Says the Longevity Industry Is Selling Mechanism, Not Health

Inigo San Millán, a sports scientist who's spent his career on the science of athletic performance, just published a pointed Substack essay arguing that the longevity industry is doing something specific and wrong: it takes legitimate biological mechanisms — mTOR, NAD+, mitochondrial function — extracts them from the human physiology they actually operate inside, and oversells them as aging "master switches."

The list of therapies he names is essentially the entire current menu: NAD+ precursors (NMN, NR), senolytics, mTOR inhibitors like rapamycin, plasmapheresis, ozone infusions, methylene blue, metformin, resveratrol, pterostilbene, spermidine, fisetin, dasatinib, CoQ10, creatine, and Urolithin A. His argument isn't that the underlying biology is wrong — it's that marketing has masqueraded as science, and that the actual longevity playbook, as Blue Zone data has shown for decades, comes from unglamorous fundamentals: consistent movement, real food, sleep, and community.

The kicker: San Millán explicitly notes that elite-sport science has been figuring out how to improve human physiology for years, and most of that work is still invisible to the consumer longevity market — which has skipped the integration step in favor of selling the molecule.

Gobble's Take: A sports scientist looked at the longevity menu and called it what it is — mechanism out of context, sold by the bottle.

Source: Inigo San Millán Substack

NAD+ Drops 50% by Age 50 — Here's the Cheapest Way to Push Back

Nicotinamide adenine dinucleotide — NAD+, the coenzyme that powers mitochondria, DNA repair, and stem cell maintenance — doesn't fade gracefully. By the time most people hit 50, levels have dropped roughly in half from their peak. The downstream effects read like a checklist of aging itself: chronic inflammation, impaired repair, accumulating senescent cells, metabolic slowdown.

A new review across more than 60 studies maps what actually moves the needle. Oral precursors like nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) can raise NAD+ levels measurably in humans, with some trials suggesting downstream improvements in metabolic markers and, in animal models, epigenetic age. But the review flags a persistent problem: oral bioavailability is inconsistent. Much of what you swallow gets metabolized before reaching target tissues, which is why some researchers have moved toward IV delivery — and why the supplement industry is racing toward more stable, better-absorbed formulations. In the meantime, lifestyle inputs matter more than most labels admit: sustained aerobic exercise, intermittent fasting, and diets rich in polyphenols (think blueberries, dark greens) each stimulate NAD+ production through separate pathways, and they stack.

The most expensive NAD+ protocol in the world still gets outperformed by the one your body runs for free — if you give it the inputs.

Gobble's Take: Before the $150 NMN bottle, try the $4 blueberry pint — the pathway is the same, the markup isn't.

Source: ChemRxiv

Fisetin Is Holding Its Own Against Pharmaceutical Senolytics — In Animals, Anyway

Fisetin — the dietary supplement aisle's current senolytic candidate — is performing surprisingly well in animal studies. According to a 2026 trends survey of 200+ longevity physicians from Hone Health, fisetin "preserves muscle mass and strength by flushing senescent cells, performing on par with some pharmaceuticals." Quercetin, often paired with it, shows similar promise, though most of the underlying data so far is cell- and animal-based rather than human.

Senescent cells, sometimes called "zombie cells," are cells that have stopped dividing but won't die — leaking inflammatory signals that accelerate the breakdown of healthy tissue. Clearing them is one of the highest-leverage targets in aging research right now, which is why pharmaceutical senolytics are in clinical pipelines and why natural compounds keeping pace with them in animals — at a fraction of the cost — keep getting pulled into the conversation.

The honest framing: the head-to-head animal data is real, but the human trial work to confirm it is still thin. The Hone Health survey calls senolytics one of the 26 most-watched longevity trends for 2026 specifically because that gap is starting to close.

Gobble's Take: A supplement-aisle flavonoid is matching a pharmaceutical drug in animal tests — and the animal data is real, even if the human data isn't yet.

Source: Hone Health

Quick Hits

• Precision longevity reaches the single-cell level: New research using single-cell sequencing is mapping how aging interventions affect individual cell types differently — meaning the same drug may extend life in one tissue while doing nothing in another, upending the idea of one-size-fits-all protocols. Frontiers in Aging
• 2026 anti-aging therapeutics preview: A new clinical review identifies epigenetic reprogramming, next-generation senolytics, and GLP-1 receptor agonists as the three therapies most likely to move from trial to prescription within the next 18 months. Expert Opinion on Pharmacotherapy

In Case You Missed It

Yesterday's top stories:

• Your Doctor's Next Prescription Might Be "Make a Friend"
• The 2,500-Year-Old Eating Rule That Beats Most Modern Diets
• The Longevity Variable Retirement Planners Never Mention
• 15 Minutes of Walking a Day Reduces Your Risk of Death by 14%